Your browser is no longer supported. Please, upgrade your browser.
PSTI Pluristem Therapeutics Inc. daily Stock Chart
Pluristem Therapeutics Inc.
Index- P/E- EPS (ttm)-7.58 Insider Own15.00% Shs Outstand25.49M Perf Week-18.48%
Market Cap227.43M Forward P/E- EPS next Y-1.21 Insider Trans47.37% Shs Float20.07M Perf Month3.81%
Income-28.80M PEG- EPS next Q-0.34 Inst Own7.20% Short Float4.75% Perf Quarter-5.96%
Sales0.02M P/S9888.26 EPS this Y45.50% Inst Trans2.77% Short Ratio1.15 Perf Half Y148.62%
Book/sh0.79 P/B11.39 EPS next Y23.40% ROA-107.80% Target Price- Perf Year89.08%
Cash/sh0.59 P/C15.37 EPS next 5Y- ROE-165.80% 52W Range2.82 - 13.29 Perf YTD128.43%
Dividend- P/FCF- EPS past 5Y-46.50% ROI- 52W High-32.28% Beta2.59
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin- 52W Low219.15% ATR0.79
Employees160 Current Ratio2.50 Sales Q/Q- Oper. Margin- RSI (14)50.59 Volatility6.60% 9.24%
OptionableYes Debt/Eq0.00 EPS Q/Q51.00% Profit Margin- Rel Volume0.80 Prev Close8.97
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume827.22K Price9.00
Recom1.60 SMA20-1.43% SMA505.86% SMA20054.95% Volume661,590 Change0.33%
Jun-19-20Initiated Jefferies Buy $12
Dec-16-19Initiated Dawson James Buy $12
Jul-22-19Initiated Ladenburg Thalmann Buy
Feb-13-17Downgrade Maxim Group Buy → Hold
Jul-19-16Resumed H.C. Wainwright Buy $3.50
Dec-22-15Reiterated Maxim Group Buy $8 → $3
Feb-03-15Reiterated Needham Buy $5 → $4
Sep-22-14Resumed Oppenheimer Outperform
Sep-08-14Initiated H.C. Wainwright Buy $4
Jan-21-14Reiterated MLV & Co Buy $4.50 → $6
Sep-16-13Upgrade Maxim Group Hold → Buy $8
Jun-04-13Downgrade Maxim Group Buy → Hold
May-31-13Initiated MLV & Co Buy $4.50
Jul-25-12Initiated Maxim Group Buy $8
Jul-24-12Downgrade WBB Securities Speculative Buy → Hold $4 → $3.75
May-22-12Initiated Needham Buy $5
Dec-09-11Initiated Global Hunter Securities Speculative Buy $5
Jun-17-11Initiated Dawson James Buy $5
May-17-11Initiated Oppenheimer Outperform $5
Mar-01-11Initiated WBB Securities Speculative Buy $4
Aug-10-20 08:44AM  
Jul-21-20 07:10AM  
Jun-23-20 09:24PM  
Jun-11-20 07:00AM  
Jun-05-20 04:05PM  
Jun-03-20 07:00AM  
Jun-01-20 11:30AM  
May-15-20 11:30AM  
May-14-20 08:00AM  
May-08-20 07:59AM  
May-05-20 09:56AM  
Apr-30-20 12:00PM  
Apr-29-20 11:30AM  
Apr-28-20 06:40AM  
Apr-27-20 06:00AM  
Apr-24-20 08:38AM  
Apr-23-20 03:05PM  
Apr-17-20 06:00AM  
Apr-15-20 08:35AM  
Apr-14-20 03:59PM  
Apr-13-20 06:00AM  
Apr-10-20 11:38AM  
Apr-09-20 08:32AM  
Apr-08-20 12:58PM  
Apr-07-20 07:50AM  
Mar-30-20 07:30AM  
Mar-26-20 08:00AM  
Mar-21-20 10:31AM  
Mar-17-20 08:47AM  
Mar-12-20 09:00AM  
Mar-03-20 07:00AM  
Feb-10-20 07:00AM  
Feb-03-20 07:00AM  
Jan-09-20 11:53AM  
Dec-17-19 07:00AM  
Dec-11-19 06:40AM  
Dec-03-19 07:00AM  
Nov-30-19 11:40AM  
Nov-19-19 11:06AM  
Nov-12-19 07:00AM  
Nov-04-19 07:00AM  
Oct-28-19 11:16AM  
Oct-08-19 02:00PM  
Sep-16-19 12:20PM  
Sep-09-19 07:00AM  
Sep-05-19 09:24AM  
Aug-21-19 07:00AM  
Jul-31-19 08:00AM  
Jul-25-19 07:21AM  
Jul-24-19 10:45AM  
Jul-22-19 09:33AM  
Jul-17-19 07:00AM  
Jul-02-19 07:00AM  
Jun-24-19 07:00AM  
Jun-17-19 07:00AM  
Jun-14-19 01:58PM  
May-15-19 07:00AM  
May-06-19 07:00AM  
Apr-29-19 07:00AM  
Apr-28-19 09:02AM  
Apr-23-19 08:00AM  
Apr-04-19 09:17AM  
Apr-03-19 04:51PM  
Mar-12-19 08:00AM  
Mar-07-19 11:01AM  
Feb-20-19 07:30AM  
Feb-14-19 06:06AM  
Feb-11-19 10:19AM  
Feb-07-19 03:31PM  
Jan-28-19 11:41AM  
Jan-22-19 07:00AM  
Jan-09-19 08:00AM  
Jan-03-19 08:30AM  
Dec-17-18 08:40AM  
Dec-13-18 11:59AM  
Dec-04-18 07:00AM  
Dec-03-18 07:00AM  
Nov-30-18 05:32AM  
Nov-29-18 07:30AM  
Nov-28-18 08:00AM  
Nov-20-18 11:20AM  
Nov-19-18 08:15AM  
Nov-12-18 07:30AM  
Nov-08-18 10:42AM  
Oct-18-18 06:30AM  
Oct-16-18 07:00AM  
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJul 31Buy9.4314,536137,0743,729,737Aug 03 06:21 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJul 30Buy9.1951,235470,8503,715,201Aug 03 06:21 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJul 29Buy9.03121,9261,100,9923,663,966Jul 30 07:13 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJul 28Buy8.4681,198686,9353,542,040Jul 29 04:12 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJul 27Buy8.3449,396411,9633,460,842Jul 28 04:13 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJun 29Buy8.41110,897932,6443,411,446Jul 07 04:12 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJun 24Buy8.0525,000201,2503,300,549Jul 07 04:12 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJun 23Buy7.674,78936,7323,275,549Jul 07 04:12 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJun 22Buy7.3659,000434,2403,270,760Jul 07 04:12 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJun 18Buy7.3649,000360,6403,211,760Jun 29 07:23 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJun 10Buy6.9125,000172,7503,162,760Jun 29 07:23 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJun 09Buy7.1572,142515,8153,137,760Jun 29 07:23 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJun 08Buy7.36178,7171,315,3573,065,618Jun 29 07:23 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJun 05Buy7.8260,000469,2002,886,901Jun 29 07:23 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJun 04Buy7.867,61059,8152,826,901Jun 29 07:23 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJun 02Buy7.57117,489889,3922,819,291Jun 29 07:23 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerJun 01Buy7.8522,796178,9492,701,802Jun 29 07:23 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerMay 31Buy7.951,79714,2862,679,006Jun 29 07:23 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerMay 28Buy8.1675,898619,3282,677,209Jun 29 07:23 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerMay 27Buy8.1490,000732,6002,601,311Jun 29 07:23 PM